A study released by the American Epilepsy Society (AES) confirms CBD may be effective in combating epilepsy. Many parents turned to CBD (Cannabidiol) after exhausting other treatment options with negative side effects or nominal results.
At first, administering “Marijuana” to kids stirred up a lot of controversies. Because CBD (Cannabidiol) has no psychoactive properties and its effects are exclusively beneficial, more parents have been open to giving it to their children.
It’s been reported that various seizure medications leave epileptic children in a fog, as opposed to the clarity that CBD gives.
While clinical trials are still underway to confirm the effectiveness of CBD oil treatment for seizures, many epileptic patients along with parents of epileptic children have reported many miraculous benefits of CBD.
The anticonvulsant nature of cannabidiol suggests that it has a therapeutic potential in at least three of the four major types of epilepsy: grand mal, cortical focal, and complex partial seizures.
In a research study, fifteen patients suffering from secondary generalized epilepsy, refractory to known antiepileptic drugs, received either 200 to 300 mg cannabidiol daily. Another fifteen patients were given a placebo. The test subjects kept this medication routine for as long as 4.5 months. Seven out of the eight epileptics receiving cannabidiol had improvement of their disease state, whereas only one placebo patient improved.
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
It has been recently shown that the phytocannabinoid cannabidiol (CBD) reduces seizure severity and lethality in the well-established in vivo model of pentylenetetrazole-induced generalized seizures, suggesting that earlier, small-scale clinical trials examining CBD effects in people with epilepsy warrant renewed attention. These results extend the anticonvulsant profile of CBD; when combined with a reported absence of psychoactive effects, this evidence strongly supports CBD as a therapeutic candidate for a diverse range of human epilepsies.
One study suggests that Cannabidiol (CBD) may be well tolerated as an adjunctive medication for seizure management and provides initial data supporting further study of cannabidiol in individuals with Sturge-Weber syndrome.